Catalyst Biosciences, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Catalyst Biosciences, Inc. - overview
Established
2003
Location
San Francisco, CA, US
Primary Industry
Pharmaceuticals
About
Founded in 2003 and based in South San Francisco, California, Catalyst Biosciences, Inc. is a drug discovery and development company, which develops catalytic bio-pharmaceutical products based on engineered human proteases.
Current Investors
Burrill & Company, HealthCare Ventures, Morgenthaler Ventures
Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals, Pharmaceuticals
Website
www.catalystbiosciences.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
Catalyst Biosciences, Inc. - timeline of key events
Catalyst Biosciences, Inc. - financials
| Fiscal Year Ended | Dec 31, 2011 | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 97,637,000 | 57,860,000 | 3,629,000 | 275,000 | 1,750,000 | 399,000 | 1,018,000 | 6,000 | - | 20,948,000 | 7,338,000 | 794,000 | - | - | - |
| % Revenue Growth (YoY) | - | (40.7%) | (93.7%) | (92.4%) | 536.4% | (77.2%) | 155.1% | (99.4%) | (100.0%) | - | (65.0%) | (89.2%) | - | - | - |
| EBITDA (USD) | (6,354,000) | (4,989,000) | (45,761,000) | (28,588,000) | (13,332,000) | (20,029,000) | (21,649,000) | (33,673,000) | (57,131,000) | (57,232,000) | (87,604,000) | (8,381,000) | - | - | - |
| Operating Income (USD) | (9,745,000) | (8,138,000) | (47,216,000) | (29,714,000) | (13,802,000) | (20,418,000) | (21,822,000) | (33,822,000) | (57,277,000) | (57,370,000) | (87,894,000) | (8,611,000) | - | - | - |
| Operating Margin | (10.0%) | (14.1%) | (1301.1%) | (10805.1%) | (788.7%) | (5117.3%) | (2143.6%) | (563700.0%) | - | (273.9%) | (1197.8%) | (1084.5%) | - | - | - |
| % EBITDA Margin | (6.5%) | (8.6%) | (1261.0%) | (10395.6%) | (761.8%) | (5019.8%) | (2126.6%) | (561216.7%) | - | (273.2%) | (1193.8%) | (1055.5%) | - | - | - |
| NET Income (USD) | (8,529,000) | (6,998,000) | (46,705,000) | (32,623,000) | (14,762,000) | (16,945,000) | (21,561,000) | (30,055,000) | (55,178,000) | (56,241,000) | (87,933,000) | (8,242,000) | - | - | - |
| % Net Margin | (8.7%) | (12.1%) | (1287.0%) | (11862.9%) | (843.5%) | (4246.9%) | (2118.0%) | (500916.7%) | - | (268.5%) | (1198.3%) | (1038.0%) | - | - | - |
Catalyst Biosciences, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| IPO | Completed | Catalyst Biosciences, Inc. | - |
Displaying 1 - 1 of 1
Catalyst Biosciences, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.